Objective:

To summarize recent developments in biopharmaceutical approvals and collaborations.

Key Findings:

• LYTENAVA could be the first FDA-approved ophthalmic formulation of bevacizumab.
• VOXZOGO improved growth velocity by 2.33 cm per year in children.
• Datroway improved median overall survival by 5.0 months compared to chemotherapy.
• Hepcludex achieved a 48% response rate in chronic hepatitis delta patients.
• Apogee's financing supports potential commercialization of zumilokibart.

Interpretation:

Limitations:

Conclusion: